Raises £1.25 Million to Accelerate Programmes

AI SummaryClose X

Solvonis Therapeutics PLC successfully raised £1.25 million (gross) through a direct subscription with institutional and strategic investors. The subscription was priced at £0.0033 per new ordinary share, representing an approximate 13% discount to the closing mid-market price on October 15, 2025. This will result in the issue of 378,787,876 new ordinary shares of £0.001 each. The company intends to use the proceeds to broaden its research and development activities across addiction, psychiatry, and neurology. Application has been made for the new ordinary shares to be admitted to trading on the Main Market of the London Stock Exchange, with admission expected around October 22, 2025. Following admission, the Company's issued ordinary share capital will comprise 6,782,767,131 ordinary shares of £0.001 each.

Disclaimer*

UK 100

Latest directors dealings